Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.580
AS - Asia 20.788
EU - Europa 13.663
SA - Sud America 2.940
Continente sconosciuto - Info sul continente non disponibili 1.673
AF - Africa 471
OC - Oceania 34
Totale 64.149
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.614
SG - Singapore 6.974
HK - Hong Kong 3.894
VN - Vietnam 3.860
IT - Italia 3.748
RU - Federazione Russa 3.017
CA - Canada 2.692
CN - Cina 2.652
BR - Brasile 2.167
IE - Irlanda 1.776
DE - Germania 1.467
SE - Svezia 1.255
BD - Bangladesh 875
IN - India 679
FR - Francia 603
GB - Regno Unito 453
AR - Argentina 276
KR - Corea 256
UA - Ucraina 255
IQ - Iraq 236
FI - Finlandia 229
ID - Indonesia 212
TR - Turchia 182
NL - Olanda 179
ZA - Sudafrica 148
PK - Pakistan 146
AT - Austria 128
MX - Messico 126
ES - Italia 118
JP - Giappone 117
CO - Colombia 109
SA - Arabia Saudita 109
PH - Filippine 108
EC - Ecuador 106
VE - Venezuela 97
PL - Polonia 96
MY - Malesia 79
UZ - Uzbekistan 58
DK - Danimarca 55
EG - Egitto 53
CL - Cile 50
PY - Paraguay 49
BE - Belgio 46
KE - Kenya 46
MA - Marocco 43
JM - Giamaica 40
JO - Giordania 38
PE - Perù 37
TN - Tunisia 37
NP - Nepal 36
DZ - Algeria 33
AE - Emirati Arabi Uniti 32
CZ - Repubblica Ceca 32
ET - Etiopia 30
CH - Svizzera 28
CR - Costa Rica 28
AU - Australia 26
AZ - Azerbaigian 26
RO - Romania 24
BO - Bolivia 22
TH - Thailandia 22
AL - Albania 21
LB - Libano 21
LT - Lituania 21
PT - Portogallo 21
IL - Israele 20
TW - Taiwan 20
UY - Uruguay 20
PS - Palestinian Territory 18
SN - Senegal 18
OM - Oman 17
IR - Iran 15
PA - Panama 13
AO - Angola 12
BG - Bulgaria 12
DO - Repubblica Dominicana 12
EU - Europa 12
HN - Honduras 12
KG - Kirghizistan 12
LY - Libia 12
GR - Grecia 10
KZ - Kazakistan 10
RS - Serbia 9
BH - Bahrain 8
NI - Nicaragua 8
NO - Norvegia 8
SK - Slovacchia (Repubblica Slovacca) 8
TT - Trinidad e Tobago 8
BY - Bielorussia 7
GA - Gabon 7
GT - Guatemala 7
HU - Ungheria 7
KW - Kuwait 7
MN - Mongolia 7
SV - El Salvador 7
MD - Moldavia 6
MM - Myanmar 6
NG - Nigeria 6
QA - Qatar 6
XK - ???statistics.table.value.countryCode.XK??? 6
Totale 62.386
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.832
Singapore 3.720
Toronto 2.417
Ashburn 2.192
San Jose 1.777
Dublin 1.719
Ann Arbor 1.271
Ho Chi Minh City 1.218
Frankfurt am Main 1.035
New York 1.030
Milan 1.028
Hanoi 1.003
Princeton 890
Santa Clara 752
Chicago 689
Fairfield 672
Council Bluffs 665
Chandler 662
The Dalles 653
Dallas 604
Los Angeles 589
Houston 480
Woodbridge 464
Lauterbourg 422
Rome 373
Moscow 363
Beijing 342
Lawrence 329
Wilmington 322
Altamura 321
Hefei 285
Buffalo 271
Seattle 265
Cambridge 250
Seoul 239
São Paulo 200
Shanghai 187
Jacksonville 179
San Diego 168
Pune 162
Dearborn 143
Columbus 138
Helsinki 137
Da Nang 136
Jakarta 133
Haiphong 124
London 111
Boardman 108
Orem 103
Baghdad 101
Tokyo 92
Andover 89
Salt Lake City 88
Rio de Janeiro 85
Nuremberg 84
Figino 80
Washington 80
Hải Dương 74
Brooklyn 73
Guangzhou 71
Warsaw 71
Johannesburg 70
Phoenix 69
Quận Bình Thạnh 69
Montreal 68
Chennai 67
Atlanta 66
Vienna 66
Munich 65
Boston 64
Turin 64
Naples 63
Nanjing 62
Dhaka 59
Thái Nguyên 57
Denver 56
Biên Hòa 54
Ha Long 50
Hangzhou 50
Kuala Lumpur 49
Tashkent 47
Vũng Tàu 47
San Francisco 46
Mumbai 44
Ninh Bình 44
Stockholm 44
Lahore 42
Amsterdam 41
Brasília 41
Florence 41
Can Tho 40
Tampa 40
Belo Horizonte 39
Fremont 39
Bergamo 38
Istanbul 38
Quito 38
Riyadh 38
Lappeenranta 37
Bắc Ninh 36
Totale 38.149
Salva come PNG Salva come JPEG
Nome #
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma 1.338
Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group 522
Estimation of lifetime costs for patients receiving a transplant: the case of liver transplantation related to hepatitis B in Italy 490
Vaccinations in Paediatric Solid Organ Transplant Candidates and Recipients 472
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 467
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 395
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 380
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 370
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 354
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 351
Health related quality of life in chronic liver diseases 346
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 341
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 329
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 328
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 323
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 319
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 315
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 312
The impact of liver disease on the health-related quality of life 312
High rates of 30-day mortality in patients with cirrhosis and COVID-19 311
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 309
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 304
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 297
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 296
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 294
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 294
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 292
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 289
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 287
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 282
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 279
Health Related Quality of Life in the Major Liver Conditions 276
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 273
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 272
Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients 269
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 268
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study 267
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group (Hepatology International, (2024), 18, 5, (1416-1430), 10.1007/s12072-024-10703-4) 266
Long-term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 264
Percutaneous management of chronic total occlusion of the portal vein: a retrospective analysis of technical aspects and outcomes 263
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 262
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 262
The Role of Imaging in Portal Vein Thrombosis: From the Diagnosis to the Interventional Radiological Management 258
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 255
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 253
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 253
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 250
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 248
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 244
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients 243
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 243
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 242
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 241
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 238
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 237
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 237
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 234
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 234
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 233
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 233
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 228
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 228
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 226
Current Endovascular Management of Arterial Complications After Pediatric Liver Transplantation in a Tertiary Center 225
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 224
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue 223
Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence 223
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 222
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 219
Non-anatomical revascularization of the portal vein in children with non-cirrhotic extrahepatic portal vein obstruction 215
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 215
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 214
Antibiotic Stewardship Based on Colonization with Multi-Drug-Resistant Bacteria in Liver Transplantation: A Narrative Review 214
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 213
Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study 212
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 211
Bergamo and Covid-19: How the Dark Can Turn to Light 210
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 207
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 207
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 206
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 205
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool 203
Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study 202
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 202
Extended criteria liver donation after circulatory death with prolonged warm ischemia: a pilot experience of normothermic regional perfusion and no subsequent ex-situ machine perfusion 202
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 197
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 193
Bulevirtide improves liver function in candidates for liver transplant with advanced HDV cirrhosis and severe portal hypertension 192
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 188
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 188
Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19 188
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 187
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation 187
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 187
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort 186
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 185
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 182
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 179
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 179
Strategie terapeutiche nella gestione del paziente con epatite cronica HCV-correlata 179
Totale 27.069
Salva come PNG Salva come JPEG
Categoria #
all - tutte 266.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 266.607
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.575 0 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20245.053 74 128 152 226 754 1.452 973 162 461 73 64 534
2024/202514.328 822 1.742 601 606 1.226 389 614 462 2.010 1.826 966 3.064
2025/202629.097 2.866 1.925 1.987 2.256 2.707 1.476 3.916 1.460 2.382 2.405 3.361 2.356
2026/20272.449 957 1.492 0 0 0 0 0 0 0 0 0 0
Totale 64.149